MARTINSRIED / MüNCHEN, GERMANY--(Marketwired - April 22, 2013) - MorphoSys AG /
MorphoSys to Start Share Buy-Back Program
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FRANKFURT: MOR) (Prime Standard Segment; TecDAX) announced
decision to repurchase its own shares on the stock market. Following
the Company's Supervisory Board, the Board of Management of MorphoSys
resolved to acquire up to 85,000 MorphoSys shares over the stock market
the time period from April 22, 2013 to May 10, 2013. On the basis of the
share price (status: April 19, 2013), this would amount to around EUR
million or up to 0.36% of the share capital.
The Company intends to use the shares for its long-term incentive
its management, but the shares can also be used for all purposes stated
authorization of the Annual General Meeting of May 19, 2011.
The relevant conditions of the shareholders' resolutions passed in the
shareholders' meeting 2011 of MorphoSys AG on the authorization to
to use its own shares shall apply. The purchase price paid per share may
more than 10 % higher or 20 % lower than the Company's share price
the opening auction in the Xetra trading system on the day of trading.
The buy-back is to be handled independently of and uninfluenced by the
through an appointed bank in compliance with the safe-harbor provisions.
MorphoSys will provide regular information on the progress of the share
program on the Company's website www.morphosys.com/share-buyback.
MorphoSys developed HuCAL, the most successful antibody library technology
the pharmaceutical industry. By successfully applying this and other
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a
pipeline of more than 70 human antibody drug candidates for the treatment
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow.
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®),
CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are
registered trademarks of
Slonomics(®) is a registered trademark of Sloning BioTechnology
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements
MorphoSys group of companies. The forward-looking statements contained
represent the judgment of MorphoSys as of the date of this release and
risks and uncertainties. Should actual conditions differ from the
assumptions, actual results and actions may differ from those
MorphoSys does not intend to update any of these forward-looking
far as the wording of the relevant press release is concerned.
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE